

# ForPatients

by Roche

Spinal Muscular Atrophy (SMA)

## A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)

**Trial Status**  
Completed

**Trial Runs In**  
7 Countries

**Trial Identifier**  
NCT02628743 2015-001589-25  
BN29854

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### ***Trial Summary:***

The purpose of this open-label, single arm study is to further evaluate long-term tolerability, safety and efficacy outcomes of olesoxime in participants with Spinal Muscular Atrophy (SMA) who previously participated in one of the following two clinical studies: TRO19622 CL E Q 1115-1 (open-label Phase Ib, multicenter, single- and multiple- dose study) or TRO19622 CL E Q 1275-1 (NCT01302600, Phase II/III, adaptive, parallel-group, double blind, randomized, placebo-controlled, multicenter, multinational study).

**Hoffmann-La Roche**  
Sponsor

**Phase 2**  
Phase

---

**NCT02628743 2015-001589-25 BN29854**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
All

**Healthy Volunteers**  
No

---